Bristol Myers Squibb (BMY) Total Liabilities (2009 - 2026)

Bristol Myers Squibb (BMY) has reported Total Liabilities for 18 consecutive years, with $65.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 15.38% year-over-year to $65.3 billion in Q2 2026; TTM through Jun 2026 was $65.3 billion, a 15.38% decrease from a year earlier, with the FY2025 full-year figure at $71.5 billion, down 6.14% from the prior year.
• Total Liabilities was $65.3 billion for Q2 2026 at Bristol Myers Squibb, down from $66.4 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $82.5 billion in Q1 2024 and troughed at $61.5 billion in Q2 2023.
• A 5-year average of $70.5 billion and a median of $69.5 billion in 2022 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities surged 32.19% in 2024 and retreated 15.38% in 2026, its largest moves.
• Over 5 years, Total Liabilities stood at $65.7 billion in 2022, then fell by 0.04% to $65.7 billion in 2023, then advanced by 16.05% to $76.2 billion in 2024, then declined by 6.14% to $71.5 billion in 2025, then retreated by 8.69% to $65.3 billion in 2026.
• The last three Total Liabilities figures came in at $65.3 billion (Q2 2026), $66.4 billion (Q1 2026), and $71.5 billion (Q4 2025), per Business Quant data.